26 March 2025 in EMBO Molecular Medicine
The intratumoral immune milieu is crucial for the success of anti-cancer immunotherapy. We show here that stromal modulation by the tubulin-binding anti-cancer drugs combretastatin A4 (CA-4) and eribulin improved tumor perfusion and anti-tumor immunity. This was achieved by reverting highly proliferative, angiogenic pericytes into a quiescent, contractile state which durably normalized the vascular bed and reduced hypoxia in mouse models of pancreatic neuroendocrine cancer, breast cancer and melanoma. The crucial event in pericyte phenotype switching was RhoA kinase activation, which distinguished CA-4 and eribulin effects from other anti-mitotic drugs such as paclitaxel and vinorelbine. Importantly, eribulin pre-treatment sensitized tumors for adoptive T cell therapy or checkpoint inhibition resulting in effector cell infiltration and better survival outcomes in mice. In breast cancer patients, eribulin neoadjuvant treatment induced pericyte maturity and RhoA kinase activity indicating similar vessel remodeling effects as seen in mice. Moreover, a contractile pericyte signature was associated with overall better survival outcome in two independent breast cancer cohorts. This underscores the potential of re-purposing specific anti-cancer drugs to enable synergistic complementation with emerging immunotherapies.
19 August 2026 in Proceedings of the National Academy of Sciences
Understanding how osteoblasts build and remodel bone matrix in vivo remains a fundamental challenge because cellular metabolism and matrix turnover are difficult to resolve across time and space within mineralized tissues. Here, we developed an integrated imaging platform combining stable isotope labeling with correlative electron microscopy and nanoscale secondary ion mass spectrometry (NanoSIMS) to visualize bone cell metabolism and matrix dynamics at nanometer resolution in vivo. This approach revealed rapid incorporation of dietary amino acids into osteoblast subcellular compartments within minutes of oral administration, followed by deposition of newly labeled extracellular matrix within hours. By linking elemental composition, isotope incorporation, and ultrastructure, we further show that cellular phosphorus signal is associated with early osteoblast amino acid incorporation. Multiday labeling revealed that newly deposited matrix is spatially associated with local osteocyte process architecture. Long-term amino acid tracing uncovered localized matrix turnover at osteocyte and osteoclast interfaces, including osteocyte-associated pericellular matrix remodeling and osteoclast association with newly formed, old, and mixed matrix regions. Finally, aging was associated with reduced osteoblast amino acid incorporation, diminished matrix deposition, and impaired osteocyte process-associated activity. Together, this work establishes a high-resolution platform for linking bone cell metabolism with matrix deposition and turnover in vivo, providing a broadly adaptable strategy to investigate skeletal aging, tissue remodeling, and metabolic dysfunction in disease.
24 March 2026 in Journal of Clinical Laboratory Analysis
Background: Ovarian cancer (OC) remains a challenging malignancy with a poor prognosis, particularly in advanced stages. Tumor‐infiltrating lymphocyte (TIL) therapy shows promise but has yielded inconsistent results in OC patients. This study aimed to identify factors predicting successful TIL isolation and expansion in OC. Methods: We performed multi‐omics profiling on tumor samples from 10 OC patients, including whole‐exome sequencing, bulk RNA sequencing, and single‐cell RNA sequencing. Results: Genomic analysis revealed heterogeneity in tumor mutation burden, copy number variations, and homologous recombination deficiency status across patients. Single‐cell profiling uncovered distinct cellular compositions in tumors, yielding successful TIL products (TIL+) vs. those that did not (TIL‐). TIL+ tumors exhibited higher immune cell infiltration, particularly CD8 + effector and effector memory T cells. Metabolic profiling revealed enhanced activity in critical T cell subtypes within TIL+ tumors. Analysis of myeloid cells and fibroblasts identified subpopulations uniquely associated with TIL+ or TIL‐ samples. Cell‐to‐cell communication network analysis highlighted potential prognostic markers and interactions influencing TIL isolation outcomes. Conclusion: Our findings provide insights into factors affecting TIL therapy efficacy in OC and suggest potential strategies for optimizing patient selection and TIL manufacturing protocols.